Clinical Trial Update: Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or Crohn's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial comparing subcutaneous versus intravenous vedolizumab in ulcerative colitis and Crohn's disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Ulcerative Colitis

Drugs mentioned

• Vedolizumab (vedolizumab)

Snippet

Sponsor: Takeda | Conditions: Ulcerative Colitis, Crohn's Disease | Phase 2 | Status: WITHDRAWN